Table 2 Summary of patient characteristics
From: Change the preprocedural fasting policy for contrast-enhanced CT: results of 127,200 cases
Fasting group (%) | Non-fasting group (%) | |
|---|---|---|
Total number of patients | 49,676 (39.05) | 77,524 (60.95) |
Gender | ||
Male | 28,210 (56.79) | 42,287 (54.55) |
Female | 21,466 (43.21) | 35,237 (45.45) |
Age (years) | ||
Mean ± standard deviation | 57 ± 13 | 60 ± 13 |
< 70 | 40,302 (81.13) | 60,721 (78.33) |
≥ 70 | 9374 (18.87) | 16,803 (21.67) |
Patient source | ||
Inpatients | 21,106 (42.49) | 40,173 (51.82) |
Outpatients | 28,570 (57.51) | 37,351 (48.18) |
Examination sites | ||
Abdominal | 30,462 (61.32) | 15,396 (19.86) |
Non-abdominal | 19,214 (38.68) | 62,128 (80.14) |
Risk factors and underlying diseases | ||
ICM-ADR history | 97 (0.20) | 165 (0.21) |
Other ADR histories | 3536 (7.12) | 6738 (8.69) |
Asthma | 110 (0.22) | 194 (0.25) |
Hypertension | 11,411 (22.97) | 22,718 (29.30) |
Coronary heart disease | 1608 (3.24) | 4668 (6.02) |
Heart failure | 173 (0.35) | 323 (0.42) |
Renal insufficiency | 99 (0.20) | 151 (0.19) |
Hyperthyroidism | 16 (0.03) | 45 (0.06) |
Tumor radio-chemotherapy | 5391 (10.85) | 5324 (6.87) |
β blockers | 1151 (2.32) | 12,965 (16.72) |
Diabetes | 2079 (4.19) | 3945 (5.09) |
ICM name | ||
Iopromide 370 | 7833 (15.77) | 12,532 (16.17) |
Iodixanol 270 | 3936 (7.92) | 5490 (7.08) |
Ioversol 320 | 6693 (13.47) | 12,244 (15.79) |
Iohexol 350 | 17,015 (34.25) | 26,764 (34.52) |
Iopamidol 350 | 5603 (11.25) | 9625 (12.42) |
Iobitridol 350 | 2993 (6.03) | 4392 (5.67) |
Iodixanol 320 | 5603 (11.28) | 6477 (8.35) |
Injection dose | ||
< 100 mL | 46,817 (94.24) | 72,579 (93.62) |
≥ 100 mL | 2859 (5.76) | 4945 (6.38) |
Injection rate | ||
< 5 mL/s | 36,836 (74.15) | 49,524 (63.88) |
≥ 5 mL/s | 12,840 (25.85) | 28,000 (36.12) |